Feb. 20 at 7:37 PM
$ALVO Combined, Aztiq Pharma Partners, Celtic Holdings S.C.A. and ATP Holdings ehf hold ~65% of outstanding shares of ALVO. All three of these groups lead back to Róbert Wessman (founder, etc.). Combined the three are flush with combined 4+ billion and massive cash flows. They bought 10 million shares in December alone to backstop the convertible offering. People bring up the debt but within 12 months ALVO will have several
$100 million in free cash flow and operating profits and within three years AVLO is projected to have
$1 billion in adjusted EBITA and
$600+ billion in free cash flow. We are right now at the exact turning point. They do not need the backstop but nice to know it is there in size. 2029 figures and conservatives multiples make this a
$25+ stock. As soon as the FDA clears this later this year the gap fills.
